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Aims Recently, bio-adrenomedullin (bio-ADM) was proposed as a congestion marker in heart failure (HF). In the present
study, we aimed to study whether bio-ADM levels at discharge from a hospital admission for worsening HF could
provide additional information on (residual) congestion status, diuretic dose titration and clinical outcomes.
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Methods
and results
Plasma bio-ADM was measured in 1236 acute HF patients in the PROTECT trial at day 7 or discharge. Median
discharge bio-ADM was 33.7 [21.5–61.5] pg/mL. Patients with higher discharge bio-ADM levels were hospitalised
longer, had higher brain natriuretic peptide levels, and poorer diuretic response (all P< 0.001). Bio-ADM was the
strongest predictor of discharge residual congestion (clinical congestion score> 3) (odds ratio 4.35, 95% confidence
interval 3.37–5.62; P< 0.001). Oedema at discharge was one of the strongest predictors of discharge bio-ADM
(𝛽 = 0.218; P< 0.001). Higher discharge loop diuretic doses were associated with a poorer diuretic response during
hospitalisation (𝛽 = 0.187; P< 0.001) and higher bio-ADM levels (𝛽 = 0.084; P = 0.020). High discharge bio-ADM
levels combined with higher use of loop diuretics were independently associated with a greater risk of 60-day HF
rehospitalisation (hazard ratio 4.02, 95% confidence interval 2.23–7.26; P< 0.001).
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Conclusion In hospitalised HF patients, elevated pre-discharge bio-ADM levels were associated with higher discharge loop diuretic
doses and reflected residual congestion. Patients with combined higher bio-ADM levels and higher loop diuretic use
at discharge had an increased risk of rehospitalisation. Assessment of discharge bio-ADM levels may be a readily
applicable marker to identify patients with residual congestion at higher risk of early hospital readmission.
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Introduction
Acute heart failure (AHF) is characterised by fluid overload and
signs and symptoms of congestion in 95% of the patients.1 As
a result, decongestive therapy using diuretics is the primary aim
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.. of treatment.1 Despite receiving diuretic therapy, a significant
number of patients are still discharged with one or more signs of
residual congestion, which is independently associated with worse
post-discharge outcomes.2–4 However, pre-discharge assessment
of residual congestion is notoriously difficult, and current clinical
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assessments such as rales, oedema, jugular venous pressure (JVP),
and chest radiographs have high inter-observer variability.4–6
Hence, there is an increasing need to assess congestion status
objectively for better discharge planning including loop diuretic
dose titration and post-discharge follow-up.
Recently, biologically active adrenomedullin (bio-ADM) was
proposed as a congestion marker.6–9 Adrenomedullin (ADM)
is a 52-amino acid vasodilatory peptide hormone secreted by
endothelial and smooth muscle cells of blood vessels and is
involved in blood pressure regulation and maintenance of vascular
integrity.6,10 ADM is produced in an inactive glycine-extended
form after proteolytic cleavage of a large precursor hormone
pro-adrenomedullin (pro-ADM).10 About 5–20% of this inactive
hormone is converted into bio-ADM.7,11 Bio-ADM levels are
elevated in conditions that reflect fluid overload, vascular leakage,
and oedema, such as sepsis, and AHF, and is predictive of adverse
short-term outcomes.6,8,9,12–15 Emerging evidence suggests that
baseline bio-ADM levels are correlated with the severity of
congestion at admission and during/after hospitalisation in AHF
patients.8,9,15 However, as a potential congestion marker, the role of
using pre-discharge bio-ADM levels to monitor residual congestion
status and accordingly optimize decongestive therapies remains
undescribed. Therefore, in the present study we aimed to inves-
tigate the hypothesis that elevated discharge bio-ADM levels are
associated with (residual) congestion and increased loop diuretic
use at discharge. Furthermore, by assessing the additive prognos-
tic value of bio-ADM on top of loop diuretic doses, we aimed
to investigate their combined ability for identifying inadequately
decongested patients at a higher risk of adverse outcomes.
Methods
Study design and procedures
Study design and main results of the Placebo-Controlled Randomized
Study of the Selective A1 Adenosine Receptor Antagonist Rolo-
fylline for Patients Hospitalized With Acute Decompensated Heart
Failure and Volume Overload to Assess Treatment Effect on Con-
gestion and Renal Function (PROTECT) trial have been published
elsewhere.16,17 Briefly, in the multicentre, randomised, double-blind
placebo-controlled PROTECT trial, 2033 patients with AHF were
randomised to rolofylline or placebo in a 2:1 ratio. Eligible patients
had brain natriuretic peptide (BNP) levels ≥500 pg/mL or N-terminal
pro brain natriuretic peptide levels ≥2000 pg/mL, ongoing intravenous
(IV) loop diuretic therapy and dyspnoea at rest or with minimal
physical activity and impaired renal function. Overall study results
were neutral.17 All enrolled patients provided written informed
consent. The trial was conducted according to the Declaration of
Helsinki and all local and national ethics committees approved the
protocol.
In the PROTECT trial, signs and symptoms of heart failure (HF)
and other biochemical measurements are available at least at baseline,
discharge and at days 2, 7 and 14. Body weight was measured from
baseline until day 4. Creatinine clearance was calculated using the
Cockcroft–Gault formula.17 Plasma bio-ADM levels were measured
in patient EDTA samples using a novel immunoassay (Sphingotec
GmbH, Henningsdorf, Germany). Measurements were available at
baseline (n = 1562) and at discharge (if discharge occurred before ..
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.. day 7), otherwise it was measured on day 7 (n = 1236).17,18 BNP
levels were measured using a highly sensitive single molecule counting
(SMC™) technology (RUO, Erenna® Immunoassay System; Singulex
Inc., Alameda, CA, USA). Further information on biomarkers measured
in the PROTECT trial has been described previously.18,19
Study population and assessments
The current study is a retrospective analysis of the PROTECT trial.
A clinical congestion score (CCS) was calculated by adding up the
individual scores of JVP (0 to 2), orthopnoea (0 to 3) and peripheral
oedema (0 to 3), yielding a maximum score of 8.2,20 Patients with
missing CCS data at day 7 (n = 461) were excluded from all analyses
involving this variable. Diuretic response was calculated as weight
change (in kg) until day 4 per 40mg of IV furosemide administered
in the first 72 h of hospital admission (or equivalents – bumetanide:
1 mg, torsemide: 20mg). Discharge loop diuretic doses were cal-
culated by adjusting the doses according to frequency, route of
administration and furosemide equivalents. Final discharge diuretic
doses were calculated as [IV/2 = oral dose]. Total cumulative diuretic
doses till day 7 were calculated as [IV + (0.5 x oral dose)], adjusting
for bioavailability. Loop diuretic doses were available in 1497 subjects
at discharge. From the initial intention-to-treat study population of
2033 subjects, patients who underwent dialysis through day 4, had
weight loss >20 kg or had missing values for day 7 bio-ADM levels
(total n = 803) were excluded, resulting in a final study population of
1230 patients (online supplementary Figure S1). The included patient
population was comparable to the excluded patient population (online
supplementary Table S1).
Statistical analysis
Continuous variables are summarised as means (± standard devia-
tion) or as median [interquartile range] as appropriate, and cate-
gorical variables are presented as number (percentage). Differences
between tertiles of bio-ADM were tested using analysis of variance
(ANOVA) or Kruskal–Wallis test for continuous variables and Pear-
son 𝜒2 for categorical variables. Normality was assessed using his-
tograms and normal quantile–quantile plots. Non-normally distributed
variables were natural log-transformed. Associations between clinical
variables and residual congestion (defined as CCS> 3) at discharge
were assessed using a logistic regression model. Multivariable lin-
ear regression models were constructed using backward elimination
to identify predictors of discharge bio-ADM levels and loop diuretic
doses. All variables with a P-value<0.10 from univariable analyses were
included.
Cox proportional hazards regression analysis was performed to
investigate the prognostic ability of bio-ADM levels individually and
combined with loop diuretic doses for endpoints. Multivariable models
were adjusted in model 1 for rolofylline treatment and for baseline
variables from the PROTECT model published previously.21 This
model includes age, previous HF hospitalisation, peripheral oedema,
systolic blood pressure, serum sodium, log blood urea nitrogen,
log creatinine and albumin. Model 2 was adjusted for baseline log
bio-ADM levels and day 7 log BNP levels in addition to model 1.
Proportional hazards assumptions were checked using Schoenfeld
residuals and log–log plots. Kaplan–Meier survival estimates were
used to investigate the prognostic ability of discharge bio-ADM levels
combined with loop diuretic doses. Differences between groups
were tested using a log-rank test. Two-tailed tests were used and a
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P-value <0.05 was considered statistically significant. All analyses were
performed using STATA/SE version 15.0 (StataCorp LLC, College
Station, TX, USA).
Results
Baseline characteristics
Baseline characteristics according to tertiles of discharge bio-ADM
levels are presented in Table 1. Median bio-ADM levels were 33.7
[21.5–61.5] pg/mL at discharge. Higher discharge bio-ADM levels
were associated with a longer duration of hospitalisation, poorer
diuretic response, worsening renal function and higher BNP
levels at discharge (all P< 0.001). Furthermore, loop diuretic
use and signs and symptoms of residual congestion, such as
a high congestion score, orthopnoea, rales, JVP, and oedema
were more prevalent across increasing tertiles of bio-ADM (all
P< 0.006). To further elucidate the relation between bio-ADM
levels and loop diuretic doses at discharge, patients were divided
into groups based on the respective medians (Table 2). Patients
with elevated discharge bio-ADM levels combined with increased
loop diuretic usage reflected a more diseased profile, as indi-
cated by elevated levels of BNP and worsening renal function
biomarkers (all P< 0.001). Interestingly, only few patients with
high bio-ADM levels were receiving lower doses of loop diuretics,
as this was the smallest of the four groups. Similar patterns
in clinical characteristics were observed when patients were
divided according to change in bio-ADM levels from baseline
to discharge in combination with loop diuretic dosing (online
supplementary Table S2). Trends across tertiles of congestion
score at discharge were comparable to that of bio-ADM (online
supplementary Table S3).
Predictors of bio-ADM levels, loop
diuretic doses, and residual congestion
at discharge
Taking the initial population of 1230 patients, after dropping miss-
ing values for discharge bio-ADM levels, 691 patients out of 1230
(56.2%) were discharged after day 7. In a multivariable linear regres-
sion model for predictors of discharge bio-ADM levels, oedema
(𝛽 = 0.218, P< 0.001) was the strongest predictor of bio-ADM
(adjusted r2 = 0.312) (Table 3). In this model, higher discharge
bio-ADM levels were also associated with higher BNP levels and
serum creatinine at discharge and a history of diabetes and atrial
fibrillation. In a univariable logistic regression model, bio-ADM was
the strongest predictor of residual congestion (as indicated by a
CCS score> 3 at discharge) (odds ratio 4.35, 95% confidence inter-
val (CI) 3.37–5.62; P< 0.001) (online supplementary Table S4).
In a multivariable linear regression model for predictors of loop
diuretics, higher loop diuretic use at discharge was independently
associated with a poorer diuretic response during hospitali-
sation (𝛽 = 0.187; P< 0.001) and higher discharge bio-ADM
levels (𝛽 = 0.084; P = 0.020) (adjusted r2 = 0.261) (online
supplementary Table S5). ..
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.. Bio-ADM levels, residual congestion,
and discharge diuretic doses
as predictors of outcomes in acute heart
failure
Log bio-ADM at discharge was independently associated with an
increased risk of all-cause mortality (hazard ratio (HR) 1.58 per
log increase, 95% CI 1.22–2.05; P= 0.001), and HF rehospitali-
sation (HR 1.42 per log increase, 95% CI 1.10–1.84; P = 0.008),
in contrast to baseline bio-ADM levels (Table 4). The curves for
180-day mortality and 60-day readmission according tertiles of
discharge bio-ADM levels have been presented in online supple-
mentary Figures S2 and S3. The Kaplan–Meier curves for 60-day
readmission due to HF for the combined groups of bio-ADM and
loop diuretic doses at discharge are presented in Figure 1. Higher
loop diuretic doses were independently associated with increased
HF rehospitalisation, irrespective of bio-ADM levels (high or low;
Figure 1 and online supplementary Table S6). Interestingly, higher
bio-ADM levels combined with higher use of loop diuretics was
associated with a four times higher risk of rehospitalisation com-
pared to the reference group (HR 4.02 per log increase, 95% CI
2.23–7.26; P< 0.001). The association remained significant even
after adjusting for the baseline PROTECT model, baseline log
bio-ADM and day 7 log BNP levels (online supplementary Table S6).
Discussion
In this study, we showed that higher levels of pre-discharge plasma
bio-ADM levels are associated with more signs and symptoms of
residual congestion and increased use of loop diuretics at discharge.
Elevated pre-discharge bio-ADM levels had additive prognostic
value on top of higher doses of loop diuretics to predict risk of
early HF hospital readmissions. Thus, bio-ADM levels measured
before discharge may be a valuable indicator of those patients that
were not sufficiently decongested and consequently have a higher
risk of readmission due to HF.
Role of bio-ADM as a congestion marker
Release of ADM is stimulated by volume overload as a protec-
tive response to limit further vascular leakage and the resulting
tissue and interstitial fluid accumulation, by maintaining the vas-
cular endothelial barrier function.6,10 Bio-ADM levels are elevated
in AHF, a condition characterized by volume overload, and are
reflective of congestion.6,8,9,12 We recently showed that bio-ADM
levels measured during hospital admission or an episode of wors-
ening signs and/or symptoms of HF were independently associated
with severity of congestion, even after adjusting for other variables
associated with congestion.8,9 In the current study, we expanded
on these findings and studied the clinical correlates associated
with elevated pre-discharge bio-ADM levels, increased use of loop
diuretic doses and the prognostic ability of discharge bio-ADM lev-
els combined with loop diuretic doses.
Recent studies have demonstrated that inadequate deconges-
tion at the time of discharge still remains a prevalent issue in AHF
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Baseline characteristics according to tertiles of day 7 or discharge bio-adrenomedullin levels
Variables Tertile 1 Tertile 2 Tertile 3 P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Patients, n 411 409 410
Bio-ADM day 7 (pg/mL) 17.6 [12.7–21.5] 33.7 [29.0–40.3] 80.5 [60.5–124.3]
Demographics
Male sex 267 (65.0) 262 (64.1) 278 (67.8) 0.500
Age (years) 70.9 (11.1) 71.3 (11.1) 69.7 (11.1) 0.099
LVEF at baseline (%) 32.5 (12.3) 32.3 (12.1) 32.4 (13.8) 0.980
Clinical profile
LOS (days) 7.0 [6.0–12.0] 8.0 [6.0–14.0] 10.0 [7.0–16.0] <0.001
CCSa 1.0 [0.0–2.0] 1.0 [1.0–2.0] 2.0 [1.0–4.0] <0.001
Improvement in dyspnoea 360 (95.5) 351 (91.4) 332 (85.8) <0.001
NYHA class III/IV 134 (36.2) 169 (44.9) 214 (58.2) <0.001
Orthopnoea ≥+2 88 (23.3) 86 (22.4) 131 (34.3) <0.001
Rales ≥1/3 lung fields 2 (0.5) 6 (1.6) 14 (3.7) 0.006
JVP ≥6 cm 59 (16.6) 92 (26.8) 138 (41.6) <0.001
Oedema ≥+ 2 8 (2.1) 19 (4.9) 91 (23.6) <0.001
Patient history
Hyperlipidaemia 220 (53.5) 195 (47.7) 204 (49.9) 0.240
DM 145 (35.3) 199 (48.7) 231 (56.3) <0.001
Hypertension 325 (79.1) 327 (80.0) 337 (82.2) 0.510
AF/atrial flutter 190 (46.5) 221 (54.3) 252 (61.8) <0.001
Stroke (beyond 2 years) 31 (7.5) 40 (9.8) 35 (8.5) 0.520
COPD/asthma/bronchitis 69 (16.8) 75 (18.3) 94 (22.9) 0.071
IHD 287 (70.0) 291 (71.1) 296 (72.2) 0.790
PCI 108 (26.3) 101 (25.2) 106 (25.9) 0.930
CABG 78 (19.1) 83 (20.6) 113 (27.7) 0.007
Pacemaker 32 (7.8) 48 (11.7) 57 (13.9) 0.019
Biventricular pacing 38 (9.2) 38 (9.3) 47 (11.5) 0.480
ICD 53 (12.9) 59 (14.4) 84 (20.5) 0.007
NYHA class 0.084
I/II 81 (20.8) 75 (19.0) 53 (13.5)
III 197 (50.6) 203 (51.5) 209 (53.3)
IV 111 (28.5) 116 (29.4) 130 (33.2)
Prior medication use (2weeks before admission)
ACEi or ARB 323 (78.6) 310 (75.8) 297 (72.4) 0.120
Beta-blocker 306 (74.5) 321 (78.5) 302 (73.7) 0.230
CCB 52 (12.7) 64 (15.6) 56 (13.7) 0.450
AI 185 (45.0) 176 (43.0) 201 (49.0) 0.210
Digoxin 107 (26.0) 105 (25.7) 139 (33.9) 0.013
Study medications
Rolofylline, [n(%)] 257 (62.5) 283 (69.2) 283 (69.0) 0.069
Dose at discharge
Loop diuretics 40.0 [40.0–80.0] 41.6 [40.0–80.0] 80.0 [40.0–160.0] <0.001
Metolazone 2.5 [2.5–2.5] 0.6 [0.6–0.9] 1.3 [0.6–1.3] 0.071
Chlorothiazide 25.0 [12.5–25.0] 25.0 [12.5–25.0] 25.0 [25.0–25.0] 0.110
Spironolactone 25.0 [25.0–50.0] 25.0 [25.0–50.0] 25.0 [25.0–50.0] 0.200
Total diuretics until day 7 (IV+ oral) 360.0 [220.0–520.0] 360.0 [251.3–600.0] 560.0 [330.0–1120.0] <0.001
Diuretic response (kg/40mg furosemide) −0.4 [−0.9 to −0.2] −0.5 [−1.0 to −0.2] −0.3 [−0.6 to −0.1] <0.001
Laboratory values
Sodium (mmol/L) 138.7 (3.7) 138.7 (4.0) 137.5 (4.6) <0.001
Potassium (mmol/L) 4.5 (0.5) 4.5 (0.6) 4.5 (0.7) 0.330
Haemoglobin (g/dL) 13.2 (1.9) 12.9 (2.1) 12.2 (2.0) <0.001
Total cholesterol (mg/dL) 165.5 [141.0–200.0] 156.0 [131.0–188.0] 134.0 [107.0–164.5] <0.001
Biomarkers
BNP (pg/mL) 192.0 [110.0–318.5] 284.0 [151.0–494.0] 344.0 [196.0–678.0] <0.001
Creatinine (mg/dL) 1.2 [1.0–1.6] 1.4 [1.1–1.8] 1.6 [1.3–2.2] <0.001
eGFR (mL/min/1.73m2) 50.0 [37.6–65.0] 45.1 [33.5–60.9] 40.7 [30.3–56.8] <0.001
Albumin (g/dL) 4.0 [3.7–4.3] 3.9 [3.6–4.2] 3.8 [3.5–4.1] <0.001
BUN (mg/dL) 28.0 [22.0–38.0] 33.0 [25.0–45.0] 40.0 [28.0–57.0] <0.001
Values are presented as mean (± standard deviation), median [interquartile range], or n (%) wherever appropriate.
Clinical variables and biomarkers presented were measured on day 7, unless stated otherwise.
ACEi, angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; AI, aldosterone inhibitor; ARB, angiotensin receptor blocker; bio-ADM, bio-adrenomedullin; BNP, brain natriuretic peptide; BUN,
blood urea nitrogen; CABG, coronary artery bypass graft; CCB, calcium channel blocker; CCS, clinical congestion score; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; eGFR,
estimated glomerular filtration rate; ICD, implantable cardioverter-defibrillator; IHD, ischaemic heart disease; IV, intravenous; JVP, jugular venous pressure; LOS, length of stay; LVEF, left ventricular ejection
fraction; NYHA, New York Heart Association; PCI, percutaneous coronary intervention.
aMaximum score 8, values are lower than usual as patients with missing values of components of the score were not dropped.
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Table 2 Baseline characteristics according to combined groups of day 7 bio-adrenomedullin levels (high or low) and
loop diuretic doses at discharge (high or low)
Variables 1: Low
bio-ADM
+ low dose
2: Low
bio-ADM
+high dose
3: High
bio-ADM
+ low dose
4: High
bio-ADM
+high dose
P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Patients, n 259 206 188 278
Bio-ADM day 1 (pg/mL) 23.9 [16.0–33.7] 27.9 [19.2–40.1] 66.9 [42.6–99.5] 74.0 [45.9–121.1]
Bio-ADM day 7 (pg/mL) 20.9 [14.4–26.1] 19.6 [14.2–25.1] 51.7 [37.9–72.2] 60.3 [43.0–90.6]
Demographics
Male sex 152 (58.7) 147 (71.4) 114 (60.6) 197 (70.9) 0.003
Age (years) 70.8 (10.9) 70.1 (11.6) 71.9 (10.7) 70.7 (11.0) 0.460
White 254 (98.1) 197 (95.6) 183 (97.3) 257 (92.4) 0.008
LVEF at baseline (%) 34.5 (12.6) 29.8 (12.0) 33.0 (11.6) 30.3 (13.7) 0.012
Clinical profile
LOS (days) 7.0 [6.0–13.0] 7.0 [4.0–9.0] 8.0 [7.0–15.0] 8.5 [6.0–14.0] <0.001
CCSa 1.0 [0.0–2.0] 1.0 [0.0–2.0] 2.0 [0.0–3.0] 2.0 [1.0–3.0] <0.001
Improvement in dyspnoea 224 (96.1) 177 (93.7) 163 (92.6) 220 (85.6) <0.001
NYHA class III/IV 92 (40.2) 60 (32.4) 81 (46.8) 131 (52.8) <0.001
Study medications
Rolofylline 30mg 156 (60.2) 140 (68.0) 130 (69.1) 201 (72.3) 0.025
Loop diuretics at discharge 40.0 [40.0–40.0] 80.0 [80.0–120.0] 40.0 [24.5–40.0] 80.0 [80.0–160.0] <0.001
Total diuretics until day 7 (IV+ oral) 270.0 [180.0–399.4] 520.0 [370.0–760.0] 300.0 [200.0–480.0] 690.0 [440.0–1165.0] <0.001
Diuretic response (kg/40mg furosemide) −0.5 [−1.0 to −0.2] −0.3 [−0.6 to −0.1] −0.6 [−1.0 to −0.3] −0.3 [−0.6 to −0.1] <0.001
Biomarkers
BNP (pg/mL) 196.5 [108.0–333.0] 204.0 [132.0–389.0] 291.0 [147.5–557.5] 319.5 [193.0–660.5] <0.001
Creatinine (mg/dL) 1.3 [1.0–1.5] 1.3 [1.1–1.7] 1.5 [1.1–2.0] 1.6 [1.3–2.1] <0.001
eGFR (mL/min/1.73m2) 49.6 [37.0–65.6] 48.0 [34.2–62.0] 40.4 [30.6–57.5] 40.6 [31.2–55.6] <0.001
Albumin (g/dL) 4.0 [3.7–4.3] 4.0 [3.7–4.3] 3.9 [3.6–4.1] 3.9 [3.6–4.1] <0.001
BUN (mg/dL) 28.0 [22.0–36.0] 33.0 [25.0–42.0] 34.0 [25.0–46.0] 39.0 [29.0–55.0] <0.001
Values are presented as mean (± standard deviation), median [interquartile range], or n (%) wherever appropriate.
Clinical variables and biomarkers presented were measured on day 7, unless stated otherwise.
bio-ADM, bio-adrenomedullin; BNP, brain natriuretic peptide; BUN, blood urea nitrogen; CCS, clinical congestion score; eGFR, estimated glomerular filtration rate; IV,
intravenous; LOS, length of stay; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.
aMaximum score 8, values are lower than usual as patients with missing values of components of the score were not dropped.
patients, which is associated with a higher risk of readmission
and mortality.2,3,20 Moreover, pre-discharge assessment of residual
congestion is still suboptimal. Though measurement of right atrial
pressure and pulmonary capillary wedge pressure using cardiac
catheterisation is considered the gold standard, this technique
is highly invasive and not used routinely.4 Non-invasive assess-
ments such as JVP, oedema, and rales are subject to inter- and
intra-observer variability, lack standardisation, and a decreasing
number of medical professionals are sufficiently skilled to assess
them.4–6 Thus, biomarkers are of interest for assessing congestion
as they are objective, and easily measurable. Though natriuretic
peptides are commonly used to assess congestion, their produc-
tion is mainly triggered by increased cardiac stretch and pressure
during a state of volume overload.6,22,23 In contrast, bio-ADM is
stimulated to maintain vascular integrity in response to tissue con-
gestion. Therefore, though both markers provide information on
congestion status, the distinct mechanisms of production suggest
that BNP may be a marker better suited for circulatory congestion
and bio-ADM for tissue congestion. In our study, bio-ADM at
discharge was associated with BNP levels and loop diuretic doses .
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.. at discharge. However, BNP levels were not associated with loop
diuretic doses; therefore, bio-ADM may be of additive value on top
of natriuretic peptides to assess pre-discharge residual congestion
status. The utility of bio-ADM further needs to be validated using
more invasive diagnostics studies such as lung ultrasound and
cardiac catheterisation, which were unfortunately not available in
this study.
Bio-ADM, loop diuretics, and risk
of rehospitalisation
In recent studies, bio-ADM was shown to be predictive of
adverse short-term outcomes in conditions such as AHF and
sepsis.8,9,12–15 In the current study, higher bio-ADM levels com-
bined with increased use of loop diuretics were associated with
a four times higher risk of readmission compared to the refer-
ence group, even after adjusting for discharge BNP and baseline
bio-ADM levels. When combined with congestion score and BNP
levels, low bio-ADM levels may help to identify patients with
resolved congestion and an even lower risk of readmission, who
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 3 Multivariable model for predictors of discharge bio-adrenomedullin levels
Variables Log bio-ADM at dischargea
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Standardized 𝜷 T-value P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Oedema 0.218 8.04 <0.001
Log BNP 0.209 7.61 <0.001
Log creatinine 0.169 6.40 <0.001
History of DM 0.111 4.27 <0.001
History of AF 0.113 4.22 <0.001
Dyspnoea on exertion 0.098 3.73 <0.001
Digoxin 0.062 2.31 0.021
History of COPD 0.053 2.09 0.037
Albumin −0.060 −2.22 0.026
Sodium −0.060 −2.32 0.021
Log total cholesterol −0.143 −5.11 <0.001
Clinical variables and biomarkers presented were measured on day 7, unless stated otherwise.
AF, atrial fibrillation; bio-ADM, bio-adrenomedullin; BNP, brain natriuretic peptide; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus.
an = 1080, r2 = 0.319, adjusted r2 = 0.312.
Table 4 Cox regression analyses for bio-adrenomedullin levels for 180-day mortality and 60-day heart failure
rehospitalisation
Outcome Events, n (%) Log bio-ADM
levels
Univariable Cox Model 1a Model 2b
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HR (95% CI)
per log
increase
P-value HR (95% CI)
per log
increase
P-value HR (95% CI)
per log
increase
P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
180-day mortality 270/1556 (17.4) Day 1 1.49 (1.30–1.70) <0.001 1.25 (1.07–1.45) 0.004 – –
186/1230 (15.1) Day 7 1.78 (1.53–2.08) <0.001 1.47 (1.24–1.75) <0.001 1.58 (1.22–2.05) 0.001
186/1230 (15.1) Difference
day 1 to 7
1.44 (1.21–1.70) <0.001 1.22 (1.02–1.45) 0.027 1.13 (0.94–1.35) 0.195
60-day HF
rehospitalisation
230/1556 (14.8) Day 1 1.10 (0.95–1.27) 0.199 1.02 (0.87–1.20) 0.783 – –
187/1230 (15.2) Day 7 1.35 (1.16–1.58) <0.001 1.28 (1.08–1.51) 0.005 1.42 (1.10–1.84) 0.008
187/1230 (15.2) Difference
day 1 to 7
1.11 (0.96–1.29) 0.171 1.02 (0.87–1.19) 0.840 1.01 (0.86–1.20) 0.884
bio-ADM, bio-adrenomedullin; CI, confidence interval; HF, heart failure; HR, hazard ratio.
aModel 1 was adjusted for rolofylline treatment and for baseline variables from the PROTECT model published previously that included age, previous HF hospitalisation,
peripheral oedema, systolic blood pressure, serum sodium, log blood urea nitrogen, log creatinine and albumin.
bModel 2 was adjusted for day 1 log bio-ADM levels and day 7 log BNP levels in addition to model 1.
could therefore be safely discharged. On the other hand, higher
bio-ADM levels may help detect patients that are inadequately
decongested, and if the patients are already receiving optimal loop
diuretic doses or are resistant to diuretic therapy, re-assessment
of treatment may be warranted. In these patients, the physi-
cian can then consider extending hospital stay and selecting an
alternative treatment strategy, such as increasing the diuretic
dose further, using IV loop diuretics, changing to another loop
diuretic type (e.g. torsemide), or combination of loop diuretic
with either a thiazide diuretic or an aldosterone antagonist.24,25
After adjusting the diuretic strategy, bio-ADM can also be used
in conjunction with other novel prognostic markers such as
proenkephalin A 119–159 (PENK). Elevated PENK levels predict .
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.. worsening renal function, glomerular and tubular dysfunction, and
are associated with a higher risk of in-hospital and post-discharge
mortality in AHF patients.15,26 As PENK levels rise faster than
creatinine during renal damage, the marker can be used to identify
patients who do not tolerate intensification of diuretic treat-
ment based on bio-ADM levels.15 In these patients, surrogate
treatment strategies such as ultrafiltration, hypertonic saline
infusion, rolofylline or vasopressin antagonist tolvaptan might
be of benefit.25
Interestingly, patients with high bio-ADM levels receiving high
loop diuretic doses formed the largest patient group in our study,
while patients with high bio-ADM levels receiving lower doses
of loop diuretics at discharge composed the smallest group. This
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Kaplan–Meier curve for 60-day heart failure
(HF) rehospitalisation for groups of combined discharge
bio-adrenomedullin (bio-ADM) levels (high or low) and loop
diuretic doses at discharge (high or low) (unadjusted). G1–4,
groups 1 to 4.
supports the assumption that patients with high bio-ADM were
already considered by the treating physician as more congested
patients than those with lower bio-ADM levels. This patient group
also reflected the presence of a more diseased profile, as they
had higher BNP levels, worse New York Heart Association class,
and a longer hospital stay compared to other groups. Thus, the
higher doses may also be due to advanced HF, which is more likely
to result in diuretic resistance and worsening renal function. The
association of the combination of bio-ADM and loop diuretic doses
with readmission but not with mortality is an important finding,
since congestion is a prominent cause of readmission due to
worsening HF, instead of mortality.4 Therefore, this finding further
supports the role of bio-ADM as a congestion marker. Moreover,
though models predicting mortality in AHF perform reasonably
well, models predicting readmission risk still remain poor.6,27 Since
this may be a preventable outcome, bio-ADM could be an easily
measurable biomarker for identifying patients warranting diuretic
therapy changes, or patients at lower risk of readmission due to HF.
In addition to its value in detecting congestion status and high-risk
patients, bio-ADM may also be a promising therapeutic target
in HF patients. Adrecizumab is a humanized, non-neutralizing,
monoclonal antibody targeted against the N-terminus of ADM.28
The antibody increases intravascular ADM concentration in a
dose-dependent manner, leading to improved vascular integrity of
blood vessels and a decrease in tissue congestion and dyspnoea
as a result. A phase II proof of concept study in patients with
worsening HF is currently underway.6
Strengths and limitations
This is the first study evaluating the associations of discharge
bio-ADM levels with (residual) congestion at discharge and its
prognostic ability combined with discharge loop diuretics to
predict outcomes in AHF. Since bio-ADM levels were available
at different time points, we were able to study the effects of ..
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.. changes in bio-ADM on clinical variables and congestion. However,
our study is limited by its retrospective design, and all analyses
are purely observational. The diagnostic and prognostic ability
of bio-ADM needs to be supported by validation in prospec-
tive studies and by more sensitive imaging studies such as cardiac
catheterisation or lung ultrasound. Furthermore, diuretic response
was only available until day 4, as weight change was only measured
from baseline until day 4 in the PROTECT trial. Additionally, the
BNP assay used in the study was not standardised. Lastly, our
results cannot be generalized to chronic HF patients, and applica-
bility to patients with mild decompensated HF, or worsening HF
cannot be conferred from this study, however we recently studied
this in the BIOSTAT-CHF dataset.8
Conclusions
In hospitalised HF patients, elevated discharge bio-ADM levels
were associated with higher discharge loop diuretic doses and
reflected residual congestion. Patients with both higher bio-ADM
levels and higher loop diuretic doses at discharge had an increased
risk of early hospital readmission for worsening HF. Assessment of
discharge bio-ADM may be a readily applicable marker to identify
patients with residual congestion at higher risk of early hospital
readmission. Future prospective studies need to establish whether
bio-ADM can be used to guide time of discharge and loop diuretic
doses pre- and post-discharge.
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